Gregal

Gregal is a prescription medication that contains the active ingredient tiotropium, supplied in an oral dosage form. It is marketed in the European Union and classified as a long‑acting muscarinic antagonist (LAMA) bronchodilator. Gregal works by selectively blocking muscarinic M3 receptors in airway smooth muscle, leading to sustained bronchodilation. The product is intended for use under medical supervision in patients with chronic respiratory conditions and lung.

Gregal is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) and for the management of asthma when a long‑acting bronchodilator is required.

- Reducing the frequency and severity of COPD exacerbations. - Improving lung function and airflow limitation in COPD patients. - Providing long‑acting bronchodilation to support asthma control. - Decreasing symptoms such as breathlessness and wheezing during daily activities. - Used as part of a comprehensive COPD or asthma management plan together with other controller medications. - Allowing once‑daily dosing to improve patient adherence to therapy.

The safety profile of Gregal reflects the pharmacology of tiotropium and includes both frequently reported and less common adverse events. Most patients experience mild, transient symptoms, while serious reactions are rare but require prompt medical attention. Patients should report any new or worsening symptoms to their healthcare provider.

Common: - Dry mouth: reduced salivary flow causing a feeling of dryness in the mouth. - Cough: mild, transient cough that may occur after inhalation. - Constipation: infrequent bowel movements or hard stools.

Serious: - Paradoxical bronchospasm: sudden worsening of breathing difficulty after use. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing requiring emergency care. - Urinary retention: difficulty initiating or maintaining urine flow.

Precautions for Gregal focus on patient factors that may influence safety or effectiveness, and on conditions that require monitoring before and during therapy. Healthcare professionals should evaluate these considerations to determine suitability and to plan appropriate follow‑up.

- Confirm COPD or asthma diagnosis and baseline lung function before starting Gregal. - Use caution in patients with narrow‑angle glaucoma or a history of urinary retention. - Check renal function; dose may need adjustment in severe renal impairment. - Discontinue if hypersensitivity to tiotropium or formulation components is observed. - Discuss pregnancy or breastfeeding status with a healthcare provider due to limited safety data.

Gregal may interact with other medications that affect anticholinergic activity or renal clearance, potentially altering its efficacy or safety. Identifying and managing these interactions helps maintain optimal bronchodilation while minimizing adverse effects.

Avoid: - Concurrent use of other long‑acting anticholinergic agents (e.g., ipratropium) due to additive anticholinergic effects. - Strong CYP3A4 inhibitors if the formulation contains a metabolized component (though tiotropium is minimally metabolized, caution is advised).

Use with caution: - Diuretics, because they may increase the risk of urinary retention. - Beta‑agonists, as combined bronchodilation may enhance therapeutic effect but requires monitoring. - Medications that affect renal function (e.g., NSAIDs, ACE inhibitors) which could alter tiotropium clearance.